

Vigmed AB announces first sales

For further information
contact:

Vigmed:
Chairman of the board
Lennart Holm
+46 70-630 856 or

CEO
Finn Ketler
+46 42 600 5311

Vigmed AB has received the first orders for their novel range of needle-protected devices and first delivery has taken place to Mavrogenis of Greece.

Following recent announcements of exclusive distributor partnerships being agreed, as well as production start-up, Vigmed AB can now announce that the first order for products has been received and shipped.

Orders have been received from, amongst others, Greece and Sweden in the first instance.

“This very important milestone for Vigmed marks a change from being a design and innovation house to being a full-blown medical device company” states Finn Ketler, CEO Vigmed. “We look forward to completing our financial goals and objectives, and helping our partners succeed with their market entries in the coming weeks, months and years.”

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 15 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: www.vigmed.com/investor